August 18, 2026 08:18 am (IST)

Make this your homepage

All Finance

BJP reshuffles top organisation seven months after Nitin Nabin's elevation | West Bengal STF arrests suspected aide of ISI 'agent' Rana Rauf in Kolkata | ‘Very hopeful’: Indian envoy Dinesh Trivedi breaks silence on PM Tarique Rahman’s proposed India visit | Shehzad Poonawalla doubles down on BJP exit, urges party to accept resignation | Tarapith tragedy: Seven pilgrims killed as hotel goes up in flames before dawn | Bengal STF nabs suspected aide of ISI 'agent' Rana Rauf in Kolkata | After SC rebuke, BCI chief apologises to NALSAR students over enrolment freeze row | Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | | Mar 31, 2016, at 07:47 pm

Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.

Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

#Raghav Chari # Executive Vice President # Proprietary Products Group # Dr Reddy

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

In Images: Amit Shah performs 'Bhoomi Pujan' of Amul's curd manufacturing plant in Kolkata Jul 19, 2026, at 10:57 pm

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am